



Pipeline Analysis Demonstrates Insufficient Candidates in Development



September 2018

- 42 (small molecule) antibiotics in clinical development
- At least 17 of the 42 antibiotics in development have the potential to treat infections caused by Gramnegative ESKAPE pathogens—a critical area of unmet need.
- But, only 1 of these 17 represents a novel class

3



Overarching priorities identified in Scientific Roadmap for Antibiotic Discovery











WHAT IS SPARK?

(Shared Platform for Antibiotic Research & Knowledge)



SPARK: An Interactive, Publicly Available Antibiotics Discovery Tool

Primary Goal Facilitate collaborative research focused on Gram-negative drug entry and efflux, leading to discovery and development of novel antibiotics.

Scope

- ✓ Small molecules
- ✓ Gram-negative pathogens
- ✓ Early discovery phase data


Non-traditional (e.g., biologics)


Gram-positive pathogens **Out of Scope**

Pre-clinical and clinical data (e.g., IND-enabling, patient data)

Features

- Free to use
- Expanded compound libraries w/ associated assay data
- Curated assay data based on assay type (MIC, IC50), rather than data source
- Enhanced data modeling and trend analyses







SPARK Officially Launched on September 21, 2018

September 21, 2018

SPARK Has Launched!

Pew announced today the rollout of its Shared Platform for Antibiotic Research and Knowledge (SPARK) – a cloud-based, publicly available, virtual laboratory that enables scientists from around the world to share data and insights, learn from past research, and generate new insights into how molecules enter and stay inside of Gram-negative bacteria.

September 21, 2018

American Chemical Society Viewpoint

DOI: 10.1021/acsinfecdis.8b00193

Shared Platform for Antibiotic Research and Knowledge: A Collaborative Tool to SPARK Antibiotic Discovery

By Joe Thomas, Marc Navre, Aileen Rubio, and Allan Coukell

9



Another third are affiliated with

academia



Recently Announced Data Contribution (...and More to Come!)

October 22, 2018

Achaogen

Biopharmaceutical company Achaogen and The Pew Charitable Trusts announced a groundbreaking agreement today to share data from Achaogen's discontinued **LpxC inhibitor** antibiotic research program on Pew's open-access SPARK.

Announcement Coming Soon!

Stay tuned for exciting announcement regarding additional data contribution from industry...

11



Become a SPARK User

- Engage the SPARK community
 - Contact Wes Kim to access SPARK (wkim@pewtrusts.org)
 - No cost to use!
- Utilize SPARK for your own research
- Suggest data sources published or unpublished
- Contribute data: <u>SPARK-data@pewtrusts.org</u>

